We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Ecolab delivered better-than-expected Q4 2025 revenue, earnings and margin expansion.
ECL's High-Tech segment tied to semiconductors and data centers is a key growth driver.
Ecolab Digital sales rose 20%, surpassing $400M in annualized revenue.
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid fourth-quarter 2025 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding macroeconomic factors persist.
This Zacks Rank #3 (Hold) stock has gained 1.6% in the last six-months period against the industry’s 2.2% decline. The S&P 500 Composite has increased 4% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $79.3 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, missed once, delivering an average surprise of 0.27%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: On the fourth-quarter earnings call, management highlighted Ecolab’s Global High-Tech segment as a key long-term growth driver, supported by semiconductor and data-center investments, with double-digit growth in 2025. The planned Ovivo Electronics acquisition, expected in 2026, should expand ultrapure water capabilities and nearly double the High-Tech business to about $900 million.
Ecolab is also advancing liquid cooling solutions for AI data centers, including 3D TRASAR technologies that can cut cooling power use by up to 10%. Meanwhile, Ecolab Digital continues to scale, with 20% sales growth and annualized revenue above $400 million, representing a $13 billion opportunity driven by AI, remote monitoring and predictive analytics.
Strong Product Portfolio With a Focus on R&D: On the fourth-quarter earnings call, management said Ecolab’s innovation pipeline remains strong, with increasing focus on digitally enabled solutions that boost customer productivity and sustainability. Platforms like 3D TRASAR and connected monitoring tools are gaining traction, helping customers optimize water, energy and operations while supporting premium pricing and deeper relationships. Management also highlighted the growing role of smart devices across customer sites, expecting deployments to exceed one million by 2026, enabling real-time monitoring, predictive insights and improved technician productivity.
Strong Q4 Results: ECL exited the fourth quarter of 2025 with better-than-expected results. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of both margins bodes well for the stock.
Per management, Ecolab’s performance in the reported quarter was led by accelerating organic sales growth across most businesses and significant operating income margin expansion. Management also confirmed that the company is driving better-than-expected savings from its One Ecolab productivity initiatives and now anticipates annualized savings to increase from $225 million to $325 million by 2027. The recent acquisition of Ovivo Electronics ultrapure water business further strengthens Ecolab’s Global High-Tech business, creating an end-to-end water circularity offering for microelectronics customers and expanding the size of one of its most significant growth engines. This looked promising for the stock.
A Factor That May Offset ECL’s Gains
Macroeconomic Factors: Ecolab operates in 170 countries, which is why its operations are subjected to unfavorable social, political and economic challenges that may be ongoing in various countries. Per the second-quarter earnings call, management acknowledged several macroeconomic challenges that are creating near-term headwinds. Tariffs and tariff-related inflation remain a pressure point, with commodity costs running in the low to mid-single-digit range and expected to persist through the back half of the year.
The company also pointed to softer demand in paper and basic industries, which weighed on its performance compared with more resilient sectors. In addition, foreign exchange movements are expected to have an unfavorable impact on expenses relative to last year.
Estimate Trend
Ecolab is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved north by 10 cents to $8.53 per share.
The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $4.03 billion, indicating an 8.9% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Key Takeaways
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a solid fourth-quarter 2025 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding macroeconomic factors persist.
This Zacks Rank #3 (Hold) stock has gained 1.6% in the last six-months period against the industry’s 2.2% decline. The S&P 500 Composite has increased 4% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $79.3 billion. It projects 14.3% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters, missed once, delivering an average surprise of 0.27%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: On the fourth-quarter earnings call, management highlighted Ecolab’s Global High-Tech segment as a key long-term growth driver, supported by semiconductor and data-center investments, with double-digit growth in 2025. The planned Ovivo Electronics acquisition, expected in 2026, should expand ultrapure water capabilities and nearly double the High-Tech business to about $900 million.
Ecolab is also advancing liquid cooling solutions for AI data centers, including 3D TRASAR technologies that can cut cooling power use by up to 10%. Meanwhile, Ecolab Digital continues to scale, with 20% sales growth and annualized revenue above $400 million, representing a $13 billion opportunity driven by AI, remote monitoring and predictive analytics.
Strong Product Portfolio With a Focus on R&D: On the fourth-quarter earnings call, management said Ecolab’s innovation pipeline remains strong, with increasing focus on digitally enabled solutions that boost customer productivity and sustainability. Platforms like 3D TRASAR and connected monitoring tools are gaining traction, helping customers optimize water, energy and operations while supporting premium pricing and deeper relationships. Management also highlighted the growing role of smart devices across customer sites, expecting deployments to exceed one million by 2026, enabling real-time monitoring, predictive insights and improved technician productivity.
Strong Q4 Results: ECL exited the fourth quarter of 2025 with better-than-expected results. The company registered a robust year-over-year uptick in its top and bottom lines, along with solid performances across all segments. The expansion of both margins bodes well for the stock.
Per management, Ecolab’s performance in the reported quarter was led by accelerating organic sales growth across most businesses and significant operating income margin expansion. Management also confirmed that the company is driving better-than-expected savings from its One Ecolab productivity initiatives and now anticipates annualized savings to increase from $225 million to $325 million by 2027. The recent acquisition of Ovivo Electronics ultrapure water business further strengthens Ecolab’s Global High-Tech business, creating an end-to-end water circularity offering for microelectronics customers and expanding the size of one of its most significant growth engines. This looked promising for the stock.
A Factor That May Offset ECL’s Gains
Macroeconomic Factors: Ecolab operates in 170 countries, which is why its operations are subjected to unfavorable social, political and economic challenges that may be ongoing in various countries. Per the second-quarter earnings call, management acknowledged several macroeconomic challenges that are creating near-term headwinds. Tariffs and tariff-related inflation remain a pressure point, with commodity costs running in the low to mid-single-digit range and expected to persist through the back half of the year.
The company also pointed to softer demand in paper and basic industries, which weighed on its performance compared with more resilient sectors. In addition, foreign exchange movements are expected to have an unfavorable impact on expenses relative to last year.
Estimate Trend
Ecolab is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has moved north by 10 cents to $8.53 per share.
The Zacks Consensus Estimate for the company’s first-quarter 2026 revenues is pegged at $4.03 billion, indicating an 8.9% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 9.3%.